- Consumer Products
- Latest 12.52
- Currency US$
- Change -0.37
- Percent Change -2.87 %
- Volume 313,878
- Thu Aug 28, 2014 12:09 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Mar 31, 2014.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Aug 7||n/a||Nov 6||n/a|
12 months ended Aug 28, 2014.
A look at major corporate events and financial announcements that are coming up.
About the Company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.